Navigation Links
Syngenta Secures EU Approval For Next Generation Fungicide
Date:11/13/2012

ement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta International AG

Media Office
CH-4002 Basel
Switzerland
Tel: +41 61 323 2323
Fax: +41 61 323 2424

www.syngenta.com

Media contacts:

Paul Barrett
Switzerland +41 61 323 2323

Daniel Braxton
Switzerland +41 61 323 2323

Analyst/Investor contacts:

Jennifer Gough
Switzerland +41 61 323 5059
USA +1 202 737 6521

Lars Oestergaard
Switzerland +41 61 323 6793
USA +1 202 737 6520


'/>"/>
SOURCE Syngenta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Syngenta and Devgen enter insect control research partnership
2. Syngenta to acquire Pasteuria Bioscience
3. Pasteuria Bioscience to be Acquired by Syngenta
4. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
5. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
6. Roka Bioscience Secures $47.5 Million in Series D Financing
7. Generex Secures Commitments for $3.6M Capital Raise
8. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
9. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
10. Bacterin Secures $25 Million Financing with OrbiMed
11. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... ... volumes of research records. , ... Reston, VA (PRWEB) January 28, 2010 -- Surety, LLC , the ... drug discovery and development company, has selected Surety,s AbsoluteProof® trusted, digital timestamping service for ...
... ... , , ... Custom Data, the underlying source of Scopus.com, the world,s,largest abstract and citation ... analysis between scientific,articles and patents. JST, as the funding agency for promoting ...
... , , , , , , , , ... Biotech Ltd. ( SVA),("Sinovac" or the "Company"), a leading China ... of 10,000,000 common,shares at $5.75 per common share. ... to an additional 1,500,000 common,shares on the same terms and conditions. ...
Cached Biology Technology:Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data 2Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data 3Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data 4Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents 2Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents 3Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents 4Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents 5Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents 6Sinovac Announces Upsizing and Pricing of Common Share Offering 2Sinovac Announces Upsizing and Pricing of Common Share Offering 3
(Date:7/9/2014)... Bacterial infections usually announce themselves with pain and fever but ... are those that are sneaky and hard to beat. Now, ... the form of tiny DNA pyramids. Published in the journal ... the nanopyramids can flag bacteria and kill more of them ... note that some infectious pathogens can lie in wait, undetectable ...
(Date:7/9/2014)... the amphibians with the highest distribution in the Iberian ... where it comes into contact with the red swamp ... by the Spaniard Germn Orizaola from the University of ... have developed a defensive response to the invasive species. ... they co-exist with the crayfish. , Numerous invasive organisms ...
(Date:7/9/2014)... N-methyl-D-aspartate receptor antagonists can alleviate the symptoms ... irreversible cognitive dysfunction and effectively scavenge amyloid ... peptide (Aβ) vaccines reduced and eliminated Aβ ... mouse model, and significantly improved behavioral and ... team, First Affiliated Hospital of China Medical ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... 2011) Proving that technological entrepreneurship can have ... fields, renowned innovator, materials scientist and applied physicist ... recipient of the 2011 $500,000 Lemelson-MIT Prize. Rogers, ... products integral to human health, fiber optics, semiconductor ...
... A new study provides support for Darwin,s hypothesis ... more closely related species than those distantly related. ... study contains the strongest direct experimental evidence yet ... species extinction occurred more frequently and more rapidly ...
... rapidly spreading amphibian disease, has reached a site near ... the entire mountainous neotropics to be free of the ... Rescue and Conservation Project, a consortium of nine U.S. ... of frogs in imminent danger of extinction. ...
Cached Biology News:Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 2Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 3Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 4New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Scientists find deadly amphibian disease in the last disease-free region of central America 2Scientists find deadly amphibian disease in the last disease-free region of central America 3
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
5 minutes from gel band to purified DNA...
...
Biology Products: